Acadia Healthcare (NASDAQ:ACHC) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Saturday.
Several other brokerages have also commented on ACHC. Credit Suisse Group reaffirmed a “neutral” rating and issued a $40.00 price target (up previously from $35.00) on shares of Acadia Healthcare in a research note on Thursday, February 22nd. Wells Fargo began coverage on Acadia Healthcare in a report on Tuesday, January 30th. They set an “outperform” rating and a $41.00 price target on the stock. Royal Bank of Canada restated a “buy” rating and set a $45.00 price target on shares of Acadia Healthcare in a report on Tuesday, February 27th. BidaskClub downgraded Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, Cantor Fitzgerald upgraded Acadia Healthcare from a “neutral” rating to an “overweight” rating in a report on Sunday, February 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $44.50.
Acadia Healthcare stock opened at $39.46 on Friday. The company has a market capitalization of $3,530.92, a PE ratio of 17.16, a price-to-earnings-growth ratio of 1.30 and a beta of 0.63. Acadia Healthcare has a 12 month low of $26.92 and a 12 month high of $54.34. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.25 and a quick ratio of 1.25.
Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.07. The firm had revenue of $724.50 million during the quarter, compared to analysts’ expectations of $713.20 million. Acadia Healthcare had a return on equity of 8.16% and a net margin of 6.92%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 earnings per share. equities analysts predict that Acadia Healthcare will post 2.45 EPS for the current fiscal year.
In other Acadia Healthcare news, Director Reeve B. Waud sold 7,698 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $42.03, for a total value of $323,546.94. Following the completion of the sale, the director now directly owns 10,088 shares in the company, valued at $423,998.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Randall P. Goldberg sold 960 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $38.47, for a total value of $36,931.20. Following the completion of the sale, the vice president now owns 6,942 shares of the company’s stock, valued at $267,058.74. The disclosure for this sale can be found here. Insiders have sold 401,360 shares of company stock valued at $15,759,096 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.
A number of large investors have recently made changes to their positions in ACHC. State of Alaska Department of Revenue bought a new stake in Acadia Healthcare in the fourth quarter worth $150,000. Tyers Asset Management LLC boosted its holdings in Acadia Healthcare by 31.8% during the fourth quarter. Tyers Asset Management LLC now owns 5,904 shares of the company’s stock valued at $193,000 after acquiring an additional 1,424 shares during the period. Xact Kapitalforvaltning AB bought a new stake in Acadia Healthcare during the fourth quarter valued at about $231,000. CIBC World Markets Inc. bought a new stake in shares of Acadia Healthcare in the fourth quarter valued at about $236,000. Finally, Arthur Zaske & Associates LLC bought a new stake in shares of Acadia Healthcare in the third quarter valued at about $283,000.
ILLEGAL ACTIVITY NOTICE: “Acadia Healthcare (ACHC) Downgraded by ValuEngine to “Sell”” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/acadia-healthcare-achc-downgraded-by-valuengine-to-sell.html.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.